Loading
A phase 2 trial of Zanidatamab, Paclitaxel / nab-paclitaxel, Docetaxel in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting.
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT07102381 by Jazz Pharmaceuticals, with 125 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-01-01. Interventions recorded: Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab. Conditions listed: HER2-positive Breast Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, Docetaxel.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, Paclitaxel / nab-paclitaxel.
Shares Jazz Pharmaceuticals, Zanidatamab, Bispecific antibodies, Trastuzumab.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, Docetaxel.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, Paclitaxel / nab-paclitaxel.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.